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FeatureRegenerative medicine spoilt for choiceEmbryonic stem cells, induced pluripotent cells, transdifferentiated cells – there 
is now a wide range of options for medical researchers trying to regenerate 
disease-affected tissues and organs. But which approach will win the day, and 
can science policy keep up with the bioethical implications of rapid progress? 
Michael Gross investigates.Green light: Colonies of mouse ES cells growing on mitotically inactivated fibroblasts stained 
while alive with monoclonal antibodies to the surface marker SSEA-1, expressed by pluripotent 
cells. (Photo: Tim Davies.)Only ten years ago, ‘stem cells’ 
was a buzz word for all kinds of 
anticipated miracle cures, following 
the first production of human 
embryonic stem (ES) cell lines from 
blastocysts (early stage embryos) 
in 1998. As embryonic stem cells 
are pluripotent, they can generate 
the specialised cells for any kind of 
organ or tissue that one may want 
to create or repair, given the right 
enticement. While some countries, 
such as Germany, had qualms about 
the use of blastocysts discarded after 
IVF, others, including the UK, took 
the pragmatic view that these would 
have been destroyed anyway and 
took the lead in a rapidly growing and 
promising field. 
Then, in 2006, Shinya Yamanaka 
showed that a cocktail of only four 
factors suffices to turn back the 
clock of embryonic development 
and turn a differentiated somatic 
cell into a pluripotent one, which 
came to be known as an induced 
pluripotent stem (iPS) cell. Earlier on, 
the cloning of Dolly the sheep had 
demonstrated that the clock can be 
turned back in a cellular environment, 
but the finding that researchers can 
achieve this in vitro with a relatively 
simple protocol came as a surprise. 
The bad news was that one of the 
factors was a known oncogene. 
While this factor could be eliminated 
eventually, it drew attention to the 
more fundamental problem that 
pluripotency includes the potential 
for the cells to become malignant. 
Recently, a third option came onto 
the scene, when direct conversion 
of one cell type into another was 
demonstrated first for mouse and 
then for human cells. Although the 
rules are still being established, 
this so called transdifferentiation 
appears to be possible even between 
completely unrelated cell types, 
without having to go via pluripotent 
cells. The magic of transdifferentiation
In February 2010, the group of  
Marius Wernig at Stanford reported 
the rapid and efficient conversion of 
mouse fibroblasts (a cell type found 
in connective tissue, which is also 
used for the production of  
iPS cells) into functional neurons  
in vitro (Nature (2010), 463, 1035–1041). 
They achieved the conversion by 
inducing only three transcription 
factors specific for the targeted  
cell type. This was the first 
conversion between unrelated cell 
lineages — previous efforts had 
shown that one type of blood cell can be converted into another, and 
different types of neurons, as well 
as pancreatic cell types, can be 
interconverted. 
Last November, the group of Mickie 
Bhatia at McMaster University at 
Hamilton, Ontario, Canada, reported 
a similar transdifferentiation success 
with human cells. This group 
had managed to convert human 
fibroblasts into blood progenitor 
cells expressing the marker CD45, 
shared by all types of leukocytes, 
without going through a pluripotent 
stage (Nature (2010), 468, 521–526). 
These progenitors then differentiated 
into a range of blood cell lineages, 
including granulocytic, monocytic, 
megakaryocytic, and erythroid cells. 
Earlier this year, the group of 
Sheng Ding at the Scripps Institute 
in La Jolla, California, reported the 
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into functional heart cells or 
cardiomyocytes (Nat. Cell Biol. 
(2011), 13, 215–222). 
By avoiding any pluripotent states 
with their associated malignancy 
risk, the transdifferentiation 
approach appears to be safer than 
either ES or iPS cells, although 
this will have to be established in 
systematic studies. However, this 
direct route is also forsaking the 
opportunity to grow stable stem 
cell lines in culture, and thus to 
produce large amounts of cells for 
regeneration. The limited availability 
of suitable cells for conversion 
may well limit the usefulness of 
the transdifferentiation route, so 
it would be too early to write off 
pluripotent cells. 
Pluripotent problems
Medical researchers now have 
three fundamentally different 
approaches to choose from, and 
it is far from clear which will offer 
the best options. Paul Fairchild, 
co-director of the Oxford Stem Cell 
Institute at the Oxford Martin School, 
comments: “Never has the landscape 
of regenerative medicine been so 
I spy: The light of a UV microscope diffracting 
through a 6-well culture plate containing 
embryonic stem cells. Image ‘Paparazzi in 
the dark’ by Christian Unger from Smile of a 
Stem Cell (www.estools.eu/estools/discovery/ 
smile-of-a-stem-cell), copyright of University 
of Sheffield, collected and curated for the 
training and outreach programme of the 
ESTOOLS consortium.promising with advances in the use 
of adult stem cells and the availability 
of both embryonic and induced 
pluripotent stem cells. Nevertheless, 
the magnitude of the obstacles 
to be overcome should never be 
underestimated. The task ahead is, 
therefore, to begin sifting the chaff 
from the wheat to determine which 
approaches might lead to robust 
clinical applications with manageable 
levels of risk.”
To begin the sifting process, 
five research groups have recently 
assessed the quality of iPS cell 
lines, as summarised in a recent 
comment in Nature by Martin 
Pera (Nature (2011), 471, 46–47). 
The studies find that genetic and 
epigenetic abnormalities are much 
more frequent in iPS cell lines than 
in ES cells. Specific problems of iPS 
cells include gross chromosomal 
aberrations, which don’t often appear 
in ES cells, mutation rates 10 times 
higher than in the fibroblasts from 
which the iPS cell lines were derived, 
and unexpected copy number 
variations (CNVs). At the epigenetic 
level, the researchers found 
imperfections in the reprogramming, 
leaving some characteristic marks 
of the cells of origin intact. There 
are indications that some of the 
faults arise by selection rather than 
accident, which would make them 
even harder to eliminate. 
On the other hand, research 
with ES cells still faces hurdles at 
the legal and bioethical front. The 
European Court of Justice currently 
deliberates a case that might end 
up with a complete ban on all 
patents based on the use of human 
ES cells. A recent statement from 
Yves Bot, the European Advocate 
General, although not legally binding, 
appeared to point in this direction. 
While acknowledging that embryonic 
stem cells are not equivalent to 
embryos in the eyes of the law, Bot 
indicated that the fact that embryonic 
cell lines are originally derived from 
fertilized human eggs means patents 
cannot be granted for techniques that 
involve the use of embryonic stem 
cells (www.eurostemcell.org).
Stem cell researcher Oliver Brüstle 
from the University of Bonn, whose 
patent on producing brain cells 
from ES cells triggered the court 
case when it was challenged by 
Greenpeace in 2004, commented: 
“The Advocate General has taken a more restrictive view than the 
European Commission or any of the 
European Member States that have 
taken a position on this issue. No-one 
in Great Britain or Sweden would 
think of questioning a patent of this 
kind.”
Putting the case in the global 
context, Brüstle said: “One wonders 
why the EU spends millions of 
Euros supporting the development 
of therapies based on embryonic 
stem cells, if practical progress 
towards the clinic is to be blocked by 
patenting restrictions. While stem cell 
technologies are already beginning 
to reach patients in the US and Asia, 
we are still discussing policy issues 
and wasting Europe’s valuable 
competitive edge.”
The decision of the court is 
expected in around May. 
Translational research
Meanwhile, researchers at the 
medical applications front are already 
working towards regenerating certain 
defective cell types from whatever 
precursor or stem cell is available. 
The group of John Kessler at the 
Northwestern University recently 
attracted media attention with a 
report of brain cells grown from 
human ES cells (Stem Cells (2011) 
DOI: 10.1002/stem.626). The cell type 
created in Kessler’s experiments 
is one that is affected by the early 
stages of Alzheimer’s disease, so the 
hope is to be able to treat the disease 
by regenerating the population of 
these cells. 
Another part of the central nervous 
system that is very popular with 
experimental medicine is the retina. 
In the quest for ways to reverse the 
loss of sight, cell-based regeneration 
is in direct competition with bio-
electronic approaches based on 
artificial sensors. At a recent meeting, 
for instance, Mandeep Singh 
from the Nuffield Department of 
Ophthalmology at the University of 
Oxford reported preliminary animal 
studies suggesting that retinal 
regeneration can be treated with 
precursor cells, which, after injection 
into the collapsed retina started to 
develop synapses and make contact 
with bipolar cells. The treatment 
was also successful in restoring 
some retina function, even though, 
intriguingly, there was a placebo 
effect in the control experiments, due 
to the body’s own cells re-colonising 
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Brain box: Certain populations of brain cells affected by degenerative diseases are among 
the prime targets of regenerative medicine. The photo shows a real human brain displayed 
as part of the About Us exhibition at At-Bristol, launched in March. Left, Steve Gaze from the 
University of Bristol’s Centre for Comparative and Clinical Anatomy, who worked closely with 
At-Bristol’s exhibition team on the development of the Real Brain exhibit. (Photo: At-Bristol.)the space created when inactive 
control material is injected into the 
collapsed retina. 
Short of creating replacement 
tissues, stem cells can be useful 
in allowing researchers to create a 
disease model in vitro. This is one of 
the approaches pursued in the field 
of Parkinson’s disease. Recently, 
researchers at Stanford University 
have cultivated brain cells derived 
from skin cells (via iPS cells) of a 
patient with Parkinson’s disease 
and have been able to observe the 
disease symptoms in the cell culture, 
specifically the accumulation of  
a-synuclein, an increase in oxidative 
stress, and an increased sensitivity to 
a range of stress factors (Cell Stem 
Cell (2011), 3, 267–280). Having an 
‘out of body’ model of the diseased 
tissue of a living patient should help 
drug development in general and 
may also enable the researchers 
to develop personalised treatment 
options in the future. 
One organ that decays dramatically 
with aging is the thymus. The loss of 
function starts in early adulthood and 
leads to changes in the composition 
of the immune system in later 
life, as evident from an increased 
susceptibility to infection and a 
weakened response to vaccinations. 
Clare Blackburn from the MRC Centre 
for Regenerative Medicine, University 
of Edinburgh, is using ES cells and 
fetal thymic stem cells in an attempt to 
bypass the bottleneck of tissue supply 
for thymus transplants. “We hope 
one day to be able to boost immune 
system function by regenerating or 
replacing the thymus, but to do this we 
need to understand the fundamental 
mechanisms which regulate the 
epithelial cells in the thymus over the 
lifespan and how these are impacted 
by aging,” Blackburn explains. “Our 
research is focused on regulation of 
thymic cell identity by key transcription 
factors, and also by the cell’s external 
environment (Nature (2010), 466,  
978–982). Work of this type is the 
essential foundation for controlling 
tissue stem cells — both in vivo and 
in vitro — with the degree of precision 
currently possible only for pluripotent 
stem cells.”Prickly questions
In fast-moving research fields like 
genomics or stem cells, politics 
can easily be left behind. As former 
MP Evan Harris told a stem cell symposium at Oxford in March, this 
problem gets even worse when the 
research involves morally complex 
issues such as dealing with human 
embryos. “Politicians don’t like these 
issues,” Harris said, “so we don’t get 
timely legislation.” Still, the UK has 
been relatively lucky due to the fact 
that the pioneering achievement of 
the first IVF birth in 1978 shocked 
politicians into creating the 1990 
Human Fertilisation and Embryo Act, 
which was then cautiously updated 
in 2008. Harris called the 2008 bill 
“a missed opportunity” as it tiptoed 
around the critical issues of current 
research and anticipated therapies.
One important outcome of the 
1990 Act was the introduction 
of the Human Fertilisation and 
Embryo Authority (HFEA), which 
not only supervised IVF clinics but 
also acted as a bioethics council 
in prickly questions surrounding 
stem cells, therapeutic cloning, and 
pre-implantation diagnostics. As the 
current, Conservative-led government 
is planning to abolish the HFEA and 
transfer some of its functions to the 
Human Tissues Authority (HTA), it is 
not yet clear what kind of guidance in bioethics questions there will be in 
the future. 
If and when human cell lines, be 
they ES or iPS cells, enter medical 
practice, the ethical and intellectual 
property issues surrounding such cell 
lines will certainly require some work, 
as a recent report from the Hinxton 
Group, an international thinktank 
dealing with stem cell policy and 
bioethics (www.hinxtongroup.org), 
points out. At the moment, there are 
stem cell banks in various places, but 
there is no central resource where 
researchers could find information 
about existing cell lines and the 
associated intellectual property 
rights. The Hinxton Group report 
recommends establishing a central 
hub for stem cell information and 
patents, along with improvements to 
international coordination of research 
and the sharing of materials and data.
At this moment, the future of 
regenerative medicine appears to be 
wide open, but it is less than clear 
whether society will be able to handle 
what this future may hold. 
Michael Gross is a science writer based at 
Oxford. He can be contacted via his web 
page at www.michaelgross.co.uk
